Products
Online Inquiry
Gypenoside XVII
Cat. No.:
0225LY-1405
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Gypenoside XVII provides a defensive mechanism against neurotoxicity triggered by Aβ25-35; it achieves this through the estrogen receptor-mediated activation of PI3K/Akt and Nrf2/ARE/HO-1 pathways, while simultaneously silencing GSK-3β signaling.
Synonym:
GP-17; Gynosaponin S; 80321-69-3; (3beta,12beta)-20-{[6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosyl]oxy}-12-hydroxydammar-24-en-3-yl beta-D-glucopyranoside; (3beta,12beta)-20-((6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranosyl)oxy)-12-hydroxydammar-24-en-3-yl beta-D-glucopyranoside
CAS No.:
80321-69-3
Compound CID:
44584555
Formula:
C48H82O18
Formula Weight:
947.15
Specification
Relative Density:
1.38 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Gypenoside XVII can be used in cell biology research to study its neuroprotective properties or its role in inducing autophagy.
Library Information
Target:
Estrogen receptor/ERR; GSK-3
Receptor:
Estrogen receptor/ERR; GSK-3β
Pathways:
PI3K/Akt/mTOR signaling; Endocrinology/Hormones; Stem cell regulation; Metabolism
Plate Number:
AOCL-19
Plate Location:
a8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
60 mg/mL; 63.35 mM
